Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-β/Smad signaling pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2023
DOI: 10.1007/s00210-023-02450-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2023. Verfasst von Yingwen Bai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Ji…. Hauptthemen laut MEDLINE: Peritoneal Fibrosis, Silymarin. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the Hospital Pharmacy Research Foundation of Changzhou Siyao Hospital and Nanjing Pharmaceutical Association, the Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Peritoneal dialysis (PD) is the mainstay of treatment for renal failure replacement therapy. Although PD has greatly improved the quality of life of end-stage renal disease (ESRD) patients, long-term PD can lead to ultrafiltration failure, which in turn causes peritoneal fibrosis (PF). Silymarin (SM) is a polyphenolic flavonoid isolated from the milk thistle (Silybum marianum) species that has a variety of pharmacological actions, including antioxidant, anti-inflammatory, antiviral, and anti-fibrotic pharmacological activities. However, the effect of SM on PF and its potential mechanisms have not been clarified. The aim of this study was to investigate the preventive effect of SM on PF in vitro and in vivo as well as elucidate the underlying mechanisms. We established PF mouse models and human pleural mesothelial cell fibrosis in vitro by intraperitoneal injection of high-glucose peritoneal dialysis solution (PDS) or transforming growth factor-β1 (TGF-β1), and evaluated the effect of SM on peritoneal fibrosis in vivo and in vitro. We found that SM alleviated peritoneal dysfunction. Meanwhile, SM inhibited the expression of fibrotic markers (TGF-β1, collagen I, fibronectin) and restored the expression of E-cadherin, BMP-7 in PF mice and TGF-β1-treated Met-5A cells. Furthermore, SM markedly down-regulated the expression of TGF-β1, p-Smad2, and p-Smad3 and up-regulated the expression of smad7. In conclusion, these findings suggested that SM may be an efficient and novel therapy for the prevention of PF through inhibition of TGF-β/Smad signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China.
- Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu Province, China.
- Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu Province, China. glg6221230@163.com.
Förderung
- the National Natural Science Foundation of China
- the Hospital Pharmacy Research Foundation of Changzhou Siyao Hospital and Nanjing Pharmaceutical Association
- the Fundamental Research Funds for the Central Universities
Zitieren
APA
Bai, Y., Wang, L., TingYang, Wang, L., & Ge, W. (2023). Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-β/Smad signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02450-4
Vancouver
Bai Y, Wang L, TingYang, Wang L, Ge W. Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-β/Smad signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02450-4
BibTeX
@article{Bai2023,
author = {Bai, Yingwen and Wang, Lulu and TingYang and Wang, Lingyun and Ge, Weihong},
title = {Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-β/Smad signaling pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2023},
doi = {10.1007/s00210-023-02450-4}
}
EUVIMED